Comparative analysis of the stability features of human alpha-defensins as candidates for the future COVID-19 therapy through molecular dynamics

Taufik Muhammad, Fakih and Dwi Syah Fitra, Ramadhan and Arfan, Arfan (2022) Comparative analysis of the stability features of human alpha-defensins as candidates for the future COVID-19 therapy through molecular dynamics. Pharmaciana: Jurnal Kefarmasian, 12 (3): 2. pp. 283-291. ISSN 2088-4559

[thumbnail of 2088-4559_12_3_2022-2.pdf]
Preview
Text
2088-4559_12_3_2022-2.pdf - Published Version

Download (425kB) | Preview

Abstract

Coronavirus 19 (COVID-19) is still a global health issue to date, SARS-CoV-2 is a novel coronavirus that is responsible for this sickness. The receptor-binding domain of the SARS-CoV-2 virus associates with angiotensin-converting enzyme 2 (ACE-2) and allows the virus to enter human cells. Natural peptides such alpha-defensin are thought to attach to the SARS-CoV-2 RBD and prohibit it from engaging with ACE-2. Molecular dynamics simulations using a computational approach are utilized to understand the stability of six alpha-defensin macromolecules using the Gromacs 2016 software. The trajectories formed are then analyzed using VMD 1.9.4 and BIOVIA Discovery Studio 2020 software. Finally, the free energy is estimated using the MM/PBSA method. The alpha-defensins 2 macromolecules were found to have the best stability based on numerous study results (trajectory visualization, RMSD, RMSF, and free energy calculations). As a result, these macromolecules could beused to build new antiviral treatments for COVID-19 infectious disease candidates.

Item Type: Article
Uncontrolled Keywords: Computational approach, COVID-19, Infectious diseases, SARS-CoV-2 RBD, Alpha-defensin, Molecular dynamics, Antiviral agents
Subjects: Medicine & Biology > Pharmacology & Pharmacological Chemistry
Depositing User: - Elfrida Meryance Saragih
Date Deposited: 25 Jan 2024 07:21
Last Modified: 25 Jan 2024 07:21
URI: https://karya.brin.go.id/id/eprint/22373

Actions (login required)

View Item
View Item